Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EPAX changes hands again

This article was originally published in The Tan Sheet

Executive Summary

Trygg Pharma acquires the omega-3 oils firm from Austevoll Seafood and promises to open new opportunities and markets for EPAX. Aalesund, Norway-based EPAX also will significantly expand its manufacturing operations under Trygg, which is jointly owned by New York investment fund Lindsay Goldberg and krill product developer Aker BioMarine. EPAX Managing Director Bjorn Refsum said Sept. 3 the "ownership change will be a great benefit to our customers and ensure further progress in the omega-3 field." Austevoll acquired EPAX in January 2007 from Ferd Private Equity Fund (1"The Tan Sheet" Jan. 1, 2007, In Brief)

You may also be interested in...

EPAX acquisition?

"EPAX AS would be the only significant omega-3 supplier to be fully integrated from fishing to high-quality omega-3 oils" if acquired by Norwegian fishery Austevoll Seafood ASA, according to EPAX CEO Bjorn Refsum. Austevoll Seafood entered into a letter of intent with Ferd Private Equity Fund for acquisition of the investment firm's EPAX shares Dec. 22. "We already see tendencies of crude fish oil supply scarcity," Refsum said. "Through Austevoll Seafood we would be able to expand our secure access to quantity as well as quality - ensuring that our products continue to meet the high standards for which EPAX's oil is known." The fishery also supports EPAX's investment plan "to ensure increased production" at the firm's plant in Aalesund, Norway, Refsum said, adding the plan should be realized in 2007...

Stockwatch: Earnings Season Catches An Early Cold As Coronavirus Sweeps In

As industry bellwether J&J kicked-off 2019 fourth-quarter and full-year earnings season for life sciences companies, its financial results left investors feeling the cold. But with coronavirus envy sweeping a raft of smaller biotech companies, J&J may have the last laugh.



Pipeline Watch: Phase III Readouts For Surufatinib, Tislelizumab

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.






Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts